These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 28585259

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, Hughes A, Holten I, Walton A, Athan E.
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [Abstract] [Full Text] [Related]

  • 3. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections.
    O'Brien DP, Robson M, Friedman ND, Walton A, McDonald A, Callan P, Hughes A, Rahdon R, Athan E.
    BMC Infect Dis; 2013 Sep 05; 13():416. PubMed ID: 24007371
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.
    O'Brien DP, Friedman ND, McDonald A, Callan P, Hughes A, Walton A, Athan E.
    PLoS Negl Trop Dis; 2018 Mar 05; 12(3):e0006357. PubMed ID: 29554101
    [Abstract] [Full Text] [Related]

  • 6. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?
    Cowan R, Athan E, Friedman ND, Hughes AJ, McDonald A, Callan P, Fyfe J, O'Brien DP.
    PLoS Negl Trop Dis; 2015 Feb 05; 9(2):e0003503. PubMed ID: 25658304
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND, Athan E, Walton AL, O'Brien DP.
    Antimicrob Agents Chemother; 2016 May 05; 60(5):2692-5. PubMed ID: 26883709
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A, Fernandez RS.
    JBI Database System Rev Implement Rep; 2017 Jan 05; 15(1):119-139. PubMed ID: 28085731
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population.
    Boyd SC, Athan E, Friedman ND, Hughes A, Walton A, Callan P, McDonald A, O'Brien DP.
    Med J Aust; 2012 Mar 19; 196(5):341-4. PubMed ID: 22432674
    [Abstract] [Full Text] [Related]

  • 16. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    Sarpong-Duah M, Frimpong M, Beissner M, Saar M, Laing K, Sarpong F, Loglo AD, Abass KM, Frempong M, Sarfo FS, Bretzel G, Wansbrough-Jones M, Phillips RO.
    PLoS Negl Trop Dis; 2017 Jul 19; 11(7):e0005695. PubMed ID: 28671942
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Paediatric Buruli ulcer in Australia.
    Walker G, Friedman DN, O'Brien MP, Cooper C, McDonald A, Callan P, O'Brien DP.
    J Paediatr Child Health; 2020 Apr 19; 56(4):636-641. PubMed ID: 31821679
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.